• TRIAL DATA

    Early tumor shrinkage predicts longer survival in metastatic CRC on intensive chemotherapy

    In 72 Vietnamese patients treated with first-line mFOLFOXIRI plus bevacizumab, 57% achieved early tumor shrinkage (≥20% reduction at 8 weeks), which was associated with greater depth of response and significantly longer progression-free survival. (Clin Med Insights Oncol)